Lausanne and Western Switzerland combine university research, life-science development and access to wider Swiss technology capital. These 16 provider families distinguish local research routes from national and European investment mandates.
Use this list to build a focused research queue. Start with your company’s stage, the evidence you have and the milestone the round should finance. Then choose a small set of relevant providers, confirm the current mandate and plan an appropriate first conversation.
Lausanne and Western Switzerland capital at a glance
This is a selective, unranked directory of 16 provider families. A venture fund, angel network, co-investor and growth or strategic investor can serve different company needs. The scope column records geographic, institutional or investment-stage context, not a claim that every organization is headquartered locally.
| Provider | Capital route | Investment scope |
|---|---|---|
| Debiopharm Innovation Fund | Corporate venture investor | Lausanne-linked; international health technology |
| Alpana Ventures | Venture firm | Swiss research and international technology networks |
| Privilège Ventures | Early-stage venture investor | Swiss and international healthcare innovation |
| VI Partners | Venture firm | Swiss-linked healthcare and technology |
| Verve Ventures | Deep-tech venture platform | European technology companies |
| Redalpine | Multi-stage technology investment adviser | Swiss roots; pan-European scope |
| Serpentine Ventures | Venture investor | Swiss startup ecosystem |
| Swisscom Ventures | Corporate-linked venture investment platform | Swiss and international startups |
| Spicehaus Partners | Early-stage venture firm | Swiss-headquartered B2B technology |
| EquityPitcher Ventures | Venture firm | B2B technology and industry networks |
| SICTIC | Angel-investor network | Swiss technology startups |
| Endeavour Vision | Healthcare technology investor | Europe and North America |
| Session VC | Entrepreneur-led investment firm | Technology-enabled growth companies |
| Swiss Founders Fund | Pre-seed and seed venture firm | Global companies; Swiss founder network |
| ND Capital | Science and technology venture firm | US and Europe; Swiss team |
| Jolt Capital | Deep-tech growth investor | European technology scale-ups |
Build a research-to-company financing map
- Document the institution, authorized technology rights and company formation status without sharing confidential IP.
- Separate a therapeutic program, engineering product and software company before choosing investors.
- Match the round to a validation milestone rather than a vague commercialization objective.
Illustrative example: a Vaud sensing spinout has an authorized commercial-development plan and a tested prototype. It compares early Swiss technology investors, prepares an industrial pilot brief and defers growth capital until commercial evidence is stronger.
Avoid this shortcut: An EPFL connection is context, not automatic eligibility for every Swiss fund. Grants and research loans are not counted as venture investors here.
16 providers to research
1. Debiopharm Innovation Fund
Corporate venture investor. Lausanne-linked; international health technology.
Debiopharm's strategic fund invests in startups transforming pharmaceutical R&D and cancer care. Debiopharm Innovation Fund official information.
Prepare before outreach: Show the workflow or evidence gap in pharma development or oncology, and separate strategic collaboration from equity.
2. Alpana Ventures
Venture firm. Swiss research and international technology networks.
Alpana's current portfolio spans tissue diagnostics, positioning technology and digital products. Alpana Ventures official information.
Prepare before outreach: Explain the technical or customer advantage and ask which current stage and strategy match.
3. Privilège Ventures
Early-stage venture investor. Swiss and international healthcare innovation.
Privilège currently emphasizes healthtech, medtech and longevity businesses combining science and technology. Privilège Ventures official information.
Prepare before outreach: Prepare scientific validation and the next development or adoption milestone, not a generic wellness pitch.
4. VI Partners
Venture firm. Swiss-linked healthcare and technology.
VI's current materials feature drug-discovery and healthcare-company financing alongside its technology investment activity. VI Partners official information.
Prepare before outreach: Identify the relevant sector team and distinguish a scientific milestone from a commercial scaling round.
5. Verve Ventures
Deep-tech venture platform. European technology companies.
Verve describes investment topics spanning resources and energy, computing and other science-intensive innovation. Verve Ventures official information.
Prepare before outreach: Explain the technical bottleneck and the customer or industrial partner who can validate adoption.
6. Redalpine
Multi-stage technology investment adviser. Swiss roots; pan-European scope.
Redalpine's current positioning combines software and science across multiple company stages. Redalpine official information.
Prepare before outreach: Connect the scientific advantage to a scalable company and confirm the relevant strategy before outreach.
7. Serpentine Ventures
Venture investor. Swiss startup ecosystem.
Serpentine publishes founder accounts of backing companies from very early development through company growth. Serpentine Ventures official information.
Prepare before outreach: Explain the stage, technical evidence and company-building support needed; confirm current vehicle availability.
8. Swisscom Ventures
Corporate-linked venture investment platform. Swiss and international startups.
Swisscom Ventures advises funds investing minority stakes in startups and draws on digital-transformation expertise. Swisscom Ventures official information.
Prepare before outreach: Show the commercial technology use case; a corporate connection is not a guaranteed customer or pilot.
9. Spicehaus Partners
Early-stage venture firm. Swiss-headquartered B2B technology.
Spicehaus explicitly targets Swiss B2B technology companies from first revenue toward international scale. Spicehaus Partners official information.
Prepare before outreach: Prepare evidence of initial revenue and explain the specific route to repeatable international sales.
10. EquityPitcher Ventures
Venture firm. B2B technology and industry networks.
EquityPitcher emphasizes industry relationships and backing technology businesses across sectors and stages. EquityPitcher Ventures official information.
Prepare before outreach: Identify the industrial buyer and explain the customer introductions or operating expertise most relevant.
11. SICTIC
Angel-investor network. Swiss technology startups.
SICTIC operates investor days and a startup deal-flow process across technology verticals. SICTIC official information.
Prepare before outreach: Use the founder screening route and confirm company requirements; presenting does not establish member investment.
12. Endeavour Vision
Healthcare technology investor. Europe and North America.
Endeavour Vision focuses on medical devices and digital health, combining investment and company-building expertise. Endeavour Vision official information.
Prepare before outreach: Prepare the development evidence, adoption pathway and capital milestone appropriate to a healthcare technology company.
13. Session VC
Entrepreneur-led investment firm. Technology-enabled growth companies.
Session's current approach is owner-operator investing, with partners committing both capital and operating time. Session VC official information.
Prepare before outreach: Explain operating performance and the partnership sought rather than assuming a standard seed-fund model.
14. Swiss Founders Fund
Pre-seed and seed venture firm. Global companies; Swiss founder network.
Swiss Founders Fund describes sector-agnostic early investing and company building with strong founding teams. Swiss Founders Fund official information.
Prepare before outreach: Show the team insight, evidence of demand and the next focused company-building milestone.
15. ND Capital
Science and technology venture firm. US and Europe; Swiss team.
ND Capital, formerly NanoDimension, invests across life, physical and data sciences with a transatlantic platform. ND Capital official information.
Prepare before outreach: Explain which scientific disciplines converge in the product and how that creates defensibility and customer value.
16. Jolt Capital
Deep-tech growth investor. European technology scale-ups.
Jolt describes growth capital for technology-rich companies across hardware and software, including photonics, materials and semiconductors. Jolt Capital official information.
Prepare before outreach: Bring operating fundamentals and a scale-up plan; do not approach a growth strategy as an unvalidated research project.
Turn the directory into your next five research actions
Choose five providers with a plausible mandate match, not five familiar logos. For each one, keep a source and one unresolved fit question beside the next action. Leave unknown information blank until you can verify it.
A compact investor-fit worksheet
Copy one record per provider. Replace the bracketed fields with company-specific evidence.
Lausanne and Western Switzerland investor research
Provider: [name and specific fund]
Official source + checked date: [URL, date]
Why our stage and technology fit: [evidence]
Geographic or institutional connection: [evidence]
Milestone this round finances: [specific result]
Open fit question: [one question]
Introduction or founder route: [verified route]
Research institution connection: [evidence or unknown]
Authorized commercialization status: [evidence or unknown]
Next technical validation: [evidence or unknown]
Owner + next action + date: [person, action, date]
Decision: [research next / ask a question / hold]Move a provider forward when the current mandate and your company evidence match. Ask a question when one material criterion is unclear. Hold when the fund is at the wrong stage, serves a different company geography or expects evidence you do not yet have. Do not treat a contact record as investor interest.
Give Aurora, Claude or Codex a focused research mission
Use this prompt with Aurora in Finta, Claude or Codex. Add only material you are authorized to share. Review the result before adding records or contacting anyone.
Be my Lausanne and Western Switzerland investor-research teammate.
Company: [one sentence, stage and location]
Technology or business model: [specific scope]
Evidence we have: [authorized facts only]
Next financing milestone: [result to fund]
Focus checks: Research institution connection; Authorized commercialization status; Next technical validation
Candidates: [paste five provider names from this guide]
Check each provider's current official sources.
Return: fit evidence, source URL/date, one open question, next action.
Separate local presence, investment reach and eligibility.
Mark missing facts unknown; do not invent cheque sizes or contacts.
Check portfolio conflicts before suggesting sensitive material.
Draft a research queue only. Do not contact or submit to anyone.Keep the next step moving
A useful shortlist connects investor fit to a relationship owner and a specific next action. Use Finta’s investor-prospecting workflow to organize the research. Keep the official source, contact context and follow-up together in your fundraising pipeline.
Before asking for an introduction, review portfolio conflicts and prepare a relevant message. The warm-introduction guide explains how to make a clear, permission-aware request. A possible path is not a completed introduction or a financing commitment.
Related research: Zurich investor routes
A common founder question
Are all these investors headquartered in Lausanne?
No. The list starts from the Lausanne founder's job and explicitly labels wider Swiss and European routes.
How this list was researched
Research reviewed on October 29, 2026 using the linked official investment, portfolio and program pages. We count related firms and vehicles as one provider family where noted. Order is not a performance ranking. Public mandate evidence does not establish uncommitted capital, an open application window or an offer to invest; confirm the current process directly. The cover is an illustrative ecosystem, not a literal map or an investor-network diagram.
Authored by Finta Editorial Team. Source review was AI-assisted; hypothetical examples are labelled illustrative and are not customer results.
Informational guidance
This content is for general informational and educational purposes, not personalized investment, financial, legal or tax advice. Finta is not a law firm. Consult your attorney or accountant about financing documents, eligibility, intellectual property, tax treatment and your company’s circumstances.